Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11603)	6/13/2018 11:58:26 AM
From: Miljenko Zuanic	Respond to of 12215

Long time ago I stopped paying ANY attention to "Frankenstein":, regardless is he right or wrong. He is playing someone else games, not my stile. Regards the Aramchol and P2b results, the question is does one believe GLMD fabricated data or not (with missing pts)? I do not believe that they fabricated data....IF they did, would they do better job? I do believe that Aramchol demonstrate dose-curve (300, 400, 600 mg, AST and ALT level), they did demonstrate NASH improvement as well as strong tendency in fibrosis improvement. It is neutral on lipids and cholesterol. I do not want to pound MGL-3196, but drug was "neutral" on fibrosis, still market awarded company with +200/share and +2.5B in EV! What was GLMD award? Few bread pie fallen from the table!